Close Menu


News on in vitro diagnostics for gastrointestinal disease.

The company plans to use the proceeds of the round to fund ongoing development and commercialization of its point-of-care diagnostic platform.

Progenity recently agreed to pay millions to three major insurers under settlement agreements related to allegations over undisclosed past business practices.

The analyzer and assay use immunofluorescent technology to detect H. pylori antigens in human stool and helps eliminate subjectivity.

The four kits are compatible with the i-Track automated analyzer for biotherapy monitoring, which received CE marking in late 2019.

The company's Curian immunoassay instrument is currently in front of the FDA, and the PediaStat will likely be submitted later this year.